companies estimate: However, mass distribution, which needs regulatory approval, will not happen this year and several vaccines are seen as necessary to meet massive global needs. ; Pfizer and German partner BioNTech SE said they had found no serious safety concerns yet and expected to seek U.S. emergency use authorization this month, raising the chance of a regulatory decision as soon as December, according to The Japan Times. If granted, the companies estimate they can roll out up to 50 million doses this year, enough to protect 25 million people, and then produce up to 1.3 billion doses in 2021. Scientists, public health officials and investors welcomed the first successful interim data from a large-scale clinical test as a watershed moment that could help turn the tide of the pandemic if the full trial results pan out. Today is a great day for science and humanity, said Pfizer Chief Executive Albert Bourla, noting the data milestone comes with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen. This news made me smile from ear to ear. Experts said they wanted to see the full trial data, but the preliminary results looked encouraging.
(news.financializer.com). As
reported in the news.
Tagged under companies estimate, safety concerns topics.